Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPG.0000000000002087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Off-Label Use of Monoclonal Antibodies for Eosinophilic Esophagitis in Humans: A Scoping Review.
Biomedicines
November 2024
Department of Pharmacy, Peking Union Medical College Hospital, 1 Shuaifuyuan Wangfujing, Beijing 100730, China.
: Eosinophilic esophagitis (EoE) is a rare, chronic immune-mediated disorder with limited treatment options. Despite the U.S.
View Article and Find Full Text PDFDisease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry.
J Asthma Allergy
October 2024
BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Introduction: Patients with severe asthma may be prescribed biologic therapies to improve disease control. The EVEREST study aimed to characterize the global disease burden of patients with severe asthma without access to biologics and those who have access but do not receive biologics, as well as the remaining unmet need despite use of these therapies.
Methods: This was a historical cohort study of patients with severe asthma (aged ≥18 years) in the International Severe Asthma Registry receiving Global Initiative for Asthma (GINA) 2018 step 5 treatment, or with uncontrolled disease at GINA step 4.
Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.
Inflamm Intest Dis
July 2024
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Article Synopsis
- Eosinophilic esophagitis (EoE) is a chronic condition driven by food allergies that causes changes in the esophagus, necessitating treatment options like medications, dietary changes, and dilation.
- Recently approved treatments include oral budesonide tablets (Jorveza) in Europe, Canada, and Australia, and an orodispersible budesonide suspension (Eohilia) in the USA, both shown to effectively induce and maintain remission in EoE patients.
- Other treatment considerations include off-label proton-pump inhibitors, which have inconsistent results, and Dupilumab, a monoclonal antibody approved for EoE treatment in multiple regions, available for older adolescents and adults who don't respond to
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!